Articles Tagged With: COVID-19
-
COVID-19 Vaccine Receipt Was Associated with Better Clinical Outcomes in U.S. Veterans
An observational study from the Department of Veterans Affairs found that individuals who received the 2024-2025 COVID-19 vaccine and the influenza vaccine on the same day had fewer emergency department visits, COVID-19-associated hospitalizations, and deaths related to COVID-19 compared to a group that only received the influenza vaccine.
-
Comprehensive Data Analysis Validates the Effectiveness and Safety of COVID-19, RSV, and Influenza Vaccination
Respiratory syncytial virus, influenza, and COVID-19 vaccines are safe and effective.
-
Comprehensive Data Analysis Validates the Effectiveness and Safety of COVID-19, RSV, and Influenza Vaccination
Respiratory syncytial virus, influenza, and COVID-19 vaccines are safe and effective.
-
COVID-19 Vaccine Receipt Was Associated with Better Clinical Outcomes in U.S. Veterans
An observational study from the Department of Veterans Affairs found that individuals who received the 2024-2025 COVID-19 vaccine and the influenza vaccine on the same day had fewer emergency department visits, COVID-19-associated hospitalizations, and deaths related to COVID-19 compared to a group that only received the influenza vaccine.
-
COVID-19 Rebound: To Retreat or to Re-Treat
Re-treatment of non-immunocompromised patients with mild-moderate COVID-19 rebound with nirmatrelvir/ritonavir provided no significant benefit.
-
COVID-19 Rebound: To Retreat or to Re-Treat
Re-treatment of non-immunocompromised patients with mild-moderate COVID-19 rebound with nirmatrelvir/ritonavir provided no significant benefit.
-
Current Recommendations for Childhood Respiratory Vaccines
Amidst prevalent vaccine hesitancy, changing governmental advisory groups, and altered recommendations, COVID immunization still is recommended for all children aged 6 through 23 months and for older children with medical risk factors.
-
The Health and Economic Burden of Long COVID in the United States
Researchers using a computational simulation model found that the current health and economic burden of long COVID already exceeds the cost of several chronic diseases and will continue to grow as COVID-19 cases increase.
-
Restricting Remdesivir in an Immune Era: No Harm, Big Savings
A quasi-experimental, eight-hospital, pre-post restriction of remdesivir to only symptomatic, oxygen-requiring, immunocompromised adults during July 2023 to June 2024 led to a 90% reduction in remdesivir use (37.7% to 4.1%) without any increase in 14- or 28-day all-cause mortality, 30-day readmission, or hospital length of stay. Medium- and high-risk covariate models confirmed no mortality signal, while an intriguing rise in intensive care unit admission and mechanical ventilation use among the few post-intervention recipients was most consistent with residual confounding and confounding by indication (i.e., the sickest patients being channeled to receive therapy). In an era of widespread hybrid immunity from Omicron-descended variants, broad remdesivir formulary restriction can be implemented safely and can yield substantial cost savings without compromising outcomes.
-
Effects of COVID-19 on Antimicrobial Resistance in U.S. Hospitals
In a retrospective cohort study, researchers found that antimicrobial-resistant (AMR) infections increased during the COVID-19 pandemic from 182 to 193 per 10,000 hospitalizations. Recent antibiotic exposure, increased illness severity, and comorbidities were associated with AMR infections.